Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) Income towards Parent Company: 2020-2025

Historic Income towards Parent Company for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • LifeStance Health's Income towards Parent Company rose 11807.96% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 8942.7%. This contributed to the annual value of -$58.4 million for FY2024, which is 6864.58% up from last year.
  • Latest data reveals that LifeStance Health reported Income towards Parent Company of $1.1 million as of Q3 2025, which was up 11807.96% from -$3.8 million recorded in Q2 2025.
  • LifeStance Health's 5-year Income towards Parent Company high stood at $1.1 million for Q3 2025, and its period low was -$120.5 million during Q3 2021.
  • Over the past 5 years, LifeStance Health's median Income towards Parent Company value was -$37.9 million (recorded in 2022), while the average stood at -$40.5 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 355670.92% in 2021, then soared by 11807.96% in 2025.
  • LifeStance Health's Income towards Parent Company (Quarter) stood at -$108.0 million in 2021, then surged by 56.81% to -$46.7 million in 2022, then increased by 3.64% to -$45.0 million in 2023, then soared by 82.05% to -$8.1 million in 2024, then skyrocketed by 113.35% to $1.1 million in 2025.
  • Its Income towards Parent Company was $1.1 million in Q3 2025, compared to -$3.8 million in Q2 2025 and $709000.0 in Q1 2025.